Teva Pharmaceutical Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
Generics business and AUSTEDO® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth …